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Abstract
Background: Inhibitors-of-Apoptosis-Proteins (IAPs) are an evolutionarily conserved family of proteins capable of 
regulating several facets of apoptosis. IAPs are frequently dysregulated in cancer, but their role in the regulation of 
apoptosis during developmental processes is not fully understood. Here we examined the expression of IAPs during 
the post-natal development of the mouse mammary gland, which is a tissue that exhibits a profound induction of 
apoptosis during involution.
Results: Six out of eight mammalian IAP family members are expressed in the mammary gland. Notably, quantitative 
PCR and immunoblotting revealed that XIAP, c-IAP1 and c-IAP2 are down-regulated in pregnancy and lactation, and 
prior to the onset of involution. In cultured mammary epithelial cells (MECs), XIAP levels decreased in response to 
inhibition of growth factor signalling. Maintaining XIAP levels in MECs by expressing exogenous XIAP protected them 
from all apoptotic stimuli tested.
Conclusions: These data suggest that the developmental regulation of IAP expression in vivo contributes to naturally 
occurring programmes of cell death.
Background
Dysregulated apoptosis is a feature of cancer, where
apoptosis resistance promotes tumour progression by
giving cancer cells a survival advantage. For example,
resistance to apoptosis induced by loss of adhesion sig-
nals allows cancer cells to metastasise [1,2]. Moreover,
intrinsic and acquired resistance to apoptosis are barriers
to successful cancer treatments. Understanding the
mechanisms that control apoptosis under normal devel-
opmental settings is important in order to provide oppor-
tunities for designing novel anti-cancer therapeutics.
The mammary gland provides a paradigm to study
mechanisms regulating developmental apoptosis [2-5].
During cycles of mammary gland development, the dif-
ferentiated epithelial cells that produce milk in lactation
undergo widespread apoptosis after weaning, as the gland
involutes and remodels to a pre-pregnant state. Elucidat-
ing the mechanisms that regulate the sensitivity of mam-
mary epithelial cells (MECs) to apoptosis will provide
insight into possible breast cancer targets [6,7]. Currently
the molecular basis of mammary involution is not fully
understood. Here we have examined the expression and
possible role in mammary gland development of a central
family of apoptosis regulators, the Inhibitors-of-Apopto-
sis-Proteins (IAPs).
IAPs are endogenous apoptosis regulators, though
recently they have been shown to have additional diverse
roles in cell regulation [8-11]. IAPs are evolutionarily
conserved from yeast to humans and are characterised by
the presence of one or more baculovirus IAP repeat (BIR)
d o m a i n s .  T h e  B I R  d o m a i n s  t a r g e t  I A P s  t o  b i n d  a n d
inhibit caspase function [8,12]. During cell death, the nat-
ural anti-apoptosis function of IAPs is overcome via com-
petition for their caspase-binding sites by Smac and Omi,
as well as by ubiquitination [13-15].
The 8 mammalian family members exhibit distinct pat-
terns of tissue expression, however almost nothing is
known about their expression and function during nor-
mal mammary gland development, although they are
acknowledged to be frequently dysregulated in breast
cancer [16,17].
Using quantitative PCR and immunoblotting we exam-
ined IAP family member expression during post-preg-
nancy mammary gland development, and discovered that
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several IAPs are down-regulated prior to the gland enter-
ing involution. We suggest that cell-autonomous regula-
tion of IAP expression might have a central role in
sensitising MECs for apoptosis that occurs during involu-
tion of the tissue.
Results
IAP expression during mammary gland development
Initial studies using RT-PCR were performed to identify
which IAPs are expressed in the mammary gland.
BRUCE, c-IAP1, c-IAP2, NAIP1, Survivin and XIAP were
detected in mouse mammary gland at the time points
examined (Figure 1). Livin cDNA was not detected at any
of the time points, suggesting that it is not expressed in
the mammary gland (data not shown). The IAP antago-
nists, Smac and Omi, were also present. Thus most of the
known IAPs and their antagonists are transcribed in the
mammary gland and are present throughout gland devel-
opment. Since RT-PCR does not reveal changes in levels
of RNA, we performed qPCR analysis. XIAP, c-IAP1 and
c-IAP2 were chosen for subsequent analysis because they
have roles in breast cancer progression [18].
The transition from lactation to involution marks the
period in development during which substantial and syn-
chronous induction of apoptosis occurs. We hypothe-
sised previously that the epithelial cells in lactating
mammary gland might become primed for rapid apopto-
sis by alterations in the levels of apoptosis regulators dur-
ing lactation [19]. To determine whether the levels of
IAPs changed from pregnancy to lactation and/or during
involution, we carried out qPCR analysis between the end
of pregnancy and 72 hours of involution. During this time
the predominant cells are MECs, and these are the cells
that undergo apoptosis at involution. In the mouse, cell
death begins within 24 hours of involution, and tissue
remodelling occurs from ~72 hours [20].
The levels of XIAP mRNA decreased between preg-
nancy day 18 and lactation day 8. As the gland entered
involution, the relative XIAP transcript abundance
remained low during the initial phase of cell death (i.e. up
to 48 hours of involution) and then returned to the level
observed at pregnancy day 18 as tissue remodelling began
(i.e. from 72 hours of involution) (Figure 2A). c-IAP1 and
c-IAP2 transcript levels were highest at the end of preg-
nancy (P18) and then decreased considerably as the
glands entered lactation. The levels then decreased fur-
ther as the gland entered involution, with expression
been lowest at 48 hrs of involution (Figure 2B, C).
To determine if the changes in IAP expression at the
RNA level reflected changes at the protein level, we
examined IAP expression by immunoblotting. STAT3,
caspases and claudin-7 were used as markers for the key
developmental stages in mammary gland development.
Activation of the transcription factor STAT3 immediately
follows the cessation of suckling and is required for the
onset of involution [21]. STAT3 phosphorylation was not
evident during pregnancy and lactation, but occurred
within 12 hours of involution and remained for at least
the following 72 hours (Figure 3Ai). Caspases are acti-
vated during apoptosis and are responsible for cell degra-
dation [22]. Expressed as inactive zymogens, caspase
cleavage (i.e. loss of full-length protein, or appearance of
cleavage fragments) indicates that activation has
occurred. Caspase-9 levels decreased at involution 12
hours and remained low until involution 48 hours; cas-
pase-3 is activated by caspase-9 and its cleaved form was
detected at involution 48 and 72 hours (Figure 3Aii).
Finally, claudin-7 is an epithelial tight junction compo-
nent expressed by mammary epithelial cells and thought
to be involved in regulating cell-ECM interactions [23].
Its levels remained equal from pregnancy through to 48
hours of involution, and then showed a marked decrease
as the gland entered the tissue remodelling stage (Figure
3Aiii).
Thus our samples represent stages in the progression of
mammary gland involution; STAT3 and caspase-9
Figure 1 IAP family members expressed during mammary gland 
development. Total RNA extracted from mammary gland tissue of vir-
gin (V), lactation day 6 (L6), involution day 4 (I4) and 2 × involution day 
2 (I2 & I2A) mice was subjected to reverse transcription. Control reac-
tions were performed simultaneously in which the reverse tran-
scriptase (RT) was omitted. cDNA was analysed by PCR with primers 
specific to each IAP (expected PCR product size is shown in brackets). 
GAPDH primers were used as a positive control (M - DNA ladder, -ve C 
- no cDNA, *- primer dimer products).
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become activated within 12 hours; death becomes maxi-
mal at around 48-72 hours with high levels of caspase-3
activated; and the tissue remodeling begins at 72 hours
post-weaning. We next examined IAP expression during
this time course.
XIAP protein levels remained constant between the
end of pregnancy and early lactation, but decreased at
lactation day 8 (Figure 3Bi). XIAP protein levels remained
low until involution 72 hours when they then returned to
a pre-lactational level. Thus, XIAP protein is expressed at
low levels in the late lactating mammary gland prior to
the onset of cell death. The protein profile is similar to the
mRNA level, but does not follow it precisely, suggesting
that XIAP is regulated by both RNA and protein process-
ing during post-pregnancy mammary gland develop-
ment.
c-IAP1 protein expression was highest at pregnancy
day 18 and decreased considerably by lactation day 2 (Fig-
ure 3Bii). In contrast, c-IAP2 levels remained unchanged
between pregnancy day 18 and lactation day 2, but
became undetectable by the time that the gland entered
involution (Figure 3Biii). Expression of both c-IAP1 and
c-IAP2 then remained undetectable throughout involu-
tion. The protein level of c-IAP1 closely matched the
qPCR profile, suggesting that c-IAP1 expression is regu-
lated at the level of transcription in post-pregnancy
development. Although the changes in transcript abun-
dance of c-IAP2 closely matched that of c-IAP1, the c-
IAP2 protein level decreased later on in lactation, which
implies that the c-IAP1 and c-IAP2 proteins are subjected
to different modes of regulation in the mammary gland.
Finally, to determine whether the changes in IAP
expression observed in vivo were due to altered expres-
sion in the mammary epithelial cells, rather than reduced
levels of stromal components such as adipocytes, we
examined IAP levels in primary MECs immediately after
isolation from the intact tissue. Quantitative PCR analysis
using primers targeted against the adipocyte-specific
genes Perilipin A and Adiponectin, demonstrated that the
purification of P18MECs had successfully removed any
adipocytes that are present in the mammary gland tissue
at this time (P18Tissue) (Figure 4A). RT-PCR and immu-
noblotting analysis showed that XIAP and cIAP2 were
indeed expressed in P18MECs (Figure 4B). We next com-
pared IAP expression in MECs isolated from pregnancy
day 18 and lactation day 7 mice (P18MEC and L7MEC
respectively). Consistent with our in vivo data, both XIAP
and c-IAP2 levels were lower at lactation day 7 compared
with pregnancy day 18 (Figure 4C). Together, these data
confirm that expression of IAPs in mammary epithelial
cells themselves decreases as the gland approaches invo-
lution.
Importantly, our results show that down-regulation of
IAPs  in vivo precedes initiator caspase activation.
Because IAPs promote cell survival, the data support a
model in which the mammary gland becomes primed for
involution during the prior developmental stage of lacta-
tion.
XIAP down-regulation occurs in primary MEC cultures
Since XIAP is a potent inhibitor of caspases, we hypothe-
sised that its down-regulation might be a mechanism to
prime cells in vivo for subsequent apoptosis. It is unlikely
that XIAP down-regulation alone would cause apoptosis
as XIAP null mice are viable. To test this hypothesis, we
determined if XIAP down-regulation is caused by factors
that promote apoptosis in MECs.
Figure 2 Quantitative PCR analysis of IAP expression during 
mammary gland development. cDNA produced from mammary 
glands isolated at the development time points shown (P - pregnancy 
(days); L - lactation (days) and I - involution (hours)) was analysed by 
quantitative PCR. β-actin was used as the internal control mRNA to 
which IAP transcript levels were normalised. The changes in IAP ex-
pression levels are shown relative to IAP expression in the pregnancy 
day 18 sample (*indicates p < 0.05) (A) XIAP (B) c-IAP1 (C) c-IAP2. Data 
shown represents the average (+/- S.E.M.) of 3 mice at each time point.
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One factor contributing to apoptosis induction in the
mammary gland is suppression of growth factor signal-
ling [5]. We therefore cultured primary MECs in the
absence of growth factors, and in the presence of the
EGFR tyrosine kinase inhibitor, Iressa [24,25]. Cleaved
caspase-3 was detected within 6 hours of growth factor
withdrawal (Figure 5Ai). At this time, ~20% of the cells
were apoptotic (Figure 5B). Addition of Iressa to the
growth factor-free media had no further effect on apop-
tosis, indicating that growth factor withdrawal is suffi-
cient to induce apoptosis.
The loss of growth factor signalling caused XIAP levels
to decrease by ~25% and ~40% after 6 and 24 hours,
respectively (Figure 5Aii). Although Iressa did not elevate
apoptosis, it caused a greater decrease in the XIAP levels
compared with growth factor withdrawal alone; 55% and
70% after 6 and 24 hours, respectively. These data dem-
onstrate that XIAP is down-regulated during the course
of growth-factor withdrawal-induced apoptosis in MECs.
Since XIAP down-regulation coincided with caspase
activation, it was important to examine whether it was
dependent or independent of active caspases. Treatment
of serum-deprived MECs with the pan-caspase inhibitor
zVAD did not rescue the decline in XIAP levels seen after
serum withdrawal (Additional file 1A, compare lanes 2 &
3, and Additional file 1B). Moreover, neither EGF nor
insulin prevented XIAP down-regulation, even though
they protected MECs from apoptosis, as judged by the
levels of active caspase 3 (Additional file 1A, compare
lanes 2, 4 and 5).
Figure 3 Protein expression during mammary gland development. Mammary gland total protein from 3 mice (a, b, and c) was immunoblotted 
with the antibodies shown (P - pregnancy (days); L - lactation (days) and I - involution (hours)). (A) Phospho-stat3 is a marker of the onset of involution. 
Blot was stripped and re-probed with total stat-3 as a loading control (i). Full-length caspase-9 represents the inactive zymogen. Cleaved caspase-3 
represents the active form (ii). Claudin-7 is a loading control for epithelial cell content between P18 days and I48 hours (iii). (B) Membranes were 
probed for XIAP, cIAP1 and cIAP2.Owens et al. BMC Developmental Biology 2010, 10:71
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Together, these data indicate that the decline in XIAP
levels is independent of caspase activity, and cannot be
rescued by EGF or insulin/IGF signalling.
Interestingly, we found that XIAP down-regulation was
a common feature of MEC apoptosis, as withdrawal of
ECM-dependent survival signals (which also occurs dur-
ing involution) and the kinase inhibitor staurosporine
(STS), both induced XIAP down-regulation (Additional
file 2).
XIAP protects mammary epithelial cells from apoptosis
Since the XIAP protein level decreased prior to mam-
mary gland involution, as well as in primary MEC cul-
tures following serum withdrawal, we reasoned that
XIAP reduction might contribute to the apoptosis execu-
tion programme, rather than being a consequence of it.
To test this hypothesis, we used the MEC line FSK7
(which can be transfected more efficiently than primary
MEC), to determine if exogenous XIAP could protect
cells from apoptosis induced by the various stimuli. FSK7
cells behaved similarly to primary MEC regarding apop-
tosis and XIAP down-regulation in response to all apop-
totic stimuli tested (Additional file 3) [25,26].
Cells were transfected with either RFP alone or RFP-
tagged XIAP (RFPXIAP) and then treated with apoptosis
inducer. Cells treated with STS showed the expected
Figure 4 IAP expression in purified MECs. Mammary epithelial cells were purified from the combined mammary gland tissue of 2 mice at the time 
points shown (P18 - pregnancy day 18, L7 - lactation day 7). (A) Quantitative PCR analysis of the levels of adipocyte-specific gene expression in whole 
tissue lysate (Tissue) and purified mammary epithelial cells (MEC). (B) Analysis of IAP expression in P18Tissue and P18MEC. (i) RT-PCR of mRNA extracted 
from P18Tissue and P18MEC was performed using primer pairs targeted against each IAP. (ii) Protein lysates were immunoblotted with antibodies 
shown. (C) IAP expression in purified MECs extracted from mice at P18 and L7 was analysed by immunoblotting.
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increase in apoptosis after 4 and 8 hours, which was res-
cued by RFPXIAP (Figure 6A, C). Similarly, RFPXIAP
prevented apoptosis induced by Iressa (Figure 6B, C) [24-
26].
These data demonstrate that XIAP is capable of inhibit-
ing apoptosis induced by a variety of stimuli. Further-
more, they suggest that the down-regulation of XIAP
contributes to rapid execution of the apoptotic pro-
gramme. This conclusion is supported by other studies
where we have shown that reducing XIAP levels by
siRNA does not directly induce apoptosis in MECs,
rather it sensitises cells to apoptosis inducers [18].
Discussion
In this study, we have demonstrated that the IAP family
members; BRUCE, c-IAP1, c-IAP2, XIAP, NAIP-1 and
Survivin are all expressed in the mouse mammary gland,
and that XIAP, c-IAP1 and c-IAP2 are differentially
expressed at different stages during the post-pregnancy
development of the tissue. Moreover in cultured MECs,
XIAP levels decrease in response to apoptosis stimuli,
while exogenous XIAP protects MECs from apoptosis.
Of particular interest is that expression of XIAP, c-IAP1
and c-IAP2 all decrease during lactation, prior to the
onset of apoptosis at involution. These data support our
previous work on the levels of Bcl-2 family proteins,
where we showed that the potent anti-apoptotic proteins,
Bcl-2, Bcl-XL and Bcl-w all decreased during lactation
and conversely, that the levels of pro-apoptotic proteins
Bak and Bad increased [19]. It is important to stress that
these global changes in expression of apoptosis regulators
in the mammary gland occur prior to the induction of
apoptosis at involution. We therefore propose that major
changes occur in the apoptosis machinery during lacta-
tion in order to prepare epithelial cells for rapid execution
as the mammary gland enters involution. These changes
in the expression profiles of apoptosis regulators in the
absence of cell death indicates that cells employ multiple
levels of control beyond bona fide cell death regulators to
govern their fate [27]. Currently, we do not know what
the mechanisms are that lead to altered IAP levels,
though they occur through changes in both mRNA and
protein levels. A current focus is to explore the relative
roles of transcriptional control as well as protein stability
in regulating IAPs in the mammary gland.
Our data also provide insight into the lack of any overt
apoptosis phenotype in XIAP, c-IAP1 and c-IAP2 null
mice, as it shows that cells can withstand the loss of one
or more of these apoptosis regulators and remain viable.
However, IAP regulation does control the sensitivity of
cells to death stimuli, and we suggest that decreasing IAP
levels during lactation may sensitise the cells to the pro-
apoptotic signals they will receive as involution is initi-
ated [28]. This idea is supported by other cases where
changes in IAP expression correlate with changes in sen-
sitivity to apoptosis [29,30].
The onset of mammary involution is determined by the
co-ordinated regulation of multiple signalling pathways
[5,31]. In addition to down-regulating pro-survival pro-
teins (as we have shown), many pro-apoptotic proteins,
such as death receptors and associated ligands (i.e. Fas,
FasL and TNFα) are upregulated at the onset of involu-
tion [32,33]. We suggest that altered levels of IAPs might
influence the efficiency of their apoptosis signalling.
Recently, XIAP has been shown to regulate cell sensi-
tivity to Fas-induced apoptosis [34,35]. Fas activates the
Figure 5 XIAP down-regulation in response to growth factor 
withdrawal. Primary mammary epithelial cells (MECs) were cultured in 
completed media (lanes 1 and 4), serum starved (lanes 2 and 5) or se-
rum starved in the presence of 10 μM Iressa (lanes 3 and 6). (A) Whole 
cell lysates were immunoblotted with antibodies shown (i). XIAP pro-
tein levels relative to calnexin were calculated using Li-cor Odyssey 
system (ii). (B) Apoptosis was scored by counting the percentage of 
apoptotic nuclei. Results shown represent the average of 3 experi-
ments +/- S.E.M. (*indicates p < 0.05; *** indicates p < 0.01).
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extrinsic (death receptor) apoptosis pathway leading to
caspase-8 activation. In most cells (known as type II) this
is insufficient to kill the cell unless the intrinsic (mito-
chondrial) pathway is activated by caspase-dependent
cleavage of Bid to form tBid. However, XIAP null cells can
be killed by Fas even in the absence of Bid. Fas and its
ligand FasL are both expressed in mammary gland by
involution 12 hours, thus reduced XIAP expression might
allow a more robust response to the Fas death signal
[32,33]. Indeed, we have previously demonstrated that
lowering XIAP levels in MECs by siRNA dramatically
enhances their apoptotic response to the related ligand
TRAIL [18].
TNFα expression is also induced early during involu-
tion [3]. Interestingly, TNFα can activate either pro-sur-
vival or pro-apoptotic signals, but it is not known how
mammary epithelial cells co-ordinate the response to
TNFα. c-IAP1 and c-IAP2 regulate cell sensitivity to
Figure 6 XIAP protects MECs from apoptosis. FSK7 cells transiently expressing monomeric RFP or RFPXIAP were treated with staurosporine (STS) 
for 4 or 8 hours cells, then fixed and stained with DAPI. (A) Apoptosis was scored as the percentage of cells with apoptotic nuclei. (B) FSK7 cells tran-
siently expressing monomeric RFP or RFPXIAP were serum starved in the presence of 10 μM Iressa for times shown and percentage apoptosis scored. 
Data shown represents the average of 3 independent experiments +/- S.E.M. (*** indicates p < 0.01). (C) Representative images of mRFP and RFPXIAP 
expressing cells (left panels and right panels, respectively) that were either left untreated (i), treated with STS for 4 hours (ii) or treated with Iressa for 
6 hours (iii). Arrows and arrowheads indicate non-apoptotic and apoptotic nuclei, respectively. Note that the RFPXIAP-expressing drug treated cells 
are negative for active caspase 3 and have non-apoptotic nuclei. In contrast RFP-expressing cells are stained positive for active-caspase 3 and have 
condensed nuclei.
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TNFα-induced apoptosis, with the down-regulation of c-
IAPs associated with a pro-apoptotic response [36,37].
Thus MECs may down-regulate c-IAPs during lactation
to ensure a pro-apoptotic response to TNFα when the
signal is received in involution.
Approximately 90% of mammary epithelium dies dur-
ing involution. Most of these cells are alveolar MECs;
however the ductal MECs survive to re-populate the
gland in subsequent pregnancies. It is not known what
determines which cells survive involution, but the intense
pro-apoptotic signalling at this time suggests that they
have increased resistance to apoptotic signals. Interest-
ingly, at 72 hours of involution XIAP mRNA and protein
expression return to pre-lactational levels. The mecha-
nism for this increase in XIAP expression is not known.
One possibility is that it may be due to increased NF-κB
signalling at this time during development, as XIAP is a
target of NF-κB [38,39]. Of note, NF-κB can inhibit apop-
tosis in MECs, and therefore it is possible that NF-κB
mediates its protection on the mammary epithelium in
part through up-regulation of XIAP. Conversely, XIAP
can activate NF-κB signalling and thus the increase in
XIAP during involution could represent part of a pro-sur-
vival feedback that protects the remaining epithelium
from undergoing apoptosis [40].
Many breast cancer cells display resistance to apoptotic
stimuli and interestingly, also have elevated IAP expres-
sion [18]. Thus, it will be important in the future to deter-
mine if ductal MECs retain high IAP expression levels as
a mechanism of evading death during involution, as this
may provide insight into breast cancer formation.
Conclusions
Cells have developed multiple mechanisms to down-reg-
ulate IAPs during apoptosis, indicating that removing
IAPs is advantageous to ensure that apoptosis occurs.
Our model of involution is that terminal differentiation of
luminal cells may include changes in transcription and
post-translational control of apoptosis-regulating pro-
teins, to allow the cells to be efficiently cleared from the
gland by apoptosis during involution. We would therefore
argue that the down-regulation of IAPs and Bcl-2 pro-
teins prior to involution in the mammary gland, is a
developmental mechanism that promotes the efficient
execution of unwanted cells at weaning.
Methods
Reagents
Unless otherwise stated chemical reagents were obtained
from Sigma.
Antibodies
Monoclonal anti-XIAP (clone 2F1) was from Bioquote.
Anti-claudin 7 was from Zymed. Anti-calnexin (C4731)
was from Sigma. Anti-cleaved caspase-3, anti-Stat 3, anti-
caspase 9 and polyclonal anti-XIAP were from Cell Sig-
naling Technology. Anti c-IAP2 was from Abcam. Anti-
cIAP1 was a generous gift from J Silke [36]. HRP-conju-
gated secondary antibodies were from Jackson Immu-
noResearch Laboratories. IR dye-conjugated secondary
antibodies were from Molecular Probes and Rockland
Laboratories.
Tissue extracts
All experiments are carried out in accordance with the
Animal scientific procedure act (ASPA 1986), governed
by the home office within the United Kingdom, each
project has to be passed by our local ethical review pro-
cess (LERP) before final acceptance from the home office.
Virgin ICR mice were mated at 8 weeks of age. Litters
were normalised to 8 pups/mother. At 10:00 am on lacta-
tion day 8, pups were removed and involution time points
were defined as the number of hours after pup removal.
The mice were euthanised by CO2 overdose. All samples
were collected at between 10:00 am - 11:00 am (involu-
tion 12 h at 10:00 pm) to reduce possible variations
caused by circadian rhythms. Samples from 3 mice were
collected at pregnancy day 18, lactation days 2, 6 and 8,
and involution 12, 24, 48 and 72 hours. Both 4th (ingui-
nal) glands were combined and the lymph nodes were
discarded. Tissues were immediately snap frozen in liquid
nitrogen, processed using a biopulveriser, and the resul-
tant powdered tissue used to extract RNA or protein.
Preparation of primary MECs
Primary MECs were prepared according to published
procedures [41]. Tissue culture dishes were prepared,
prior to mammary cell preparation. Stock rat-tail type-I
collagen in 0.1% acetic acid was diluted in PBS to a final
c o n c e n t r a t i o n  o f  1 0  μ g / m l ,  a n d  t h e n  u s e d  t o  c o a t  t h e
dishes which were then incubated overnight at 4°C. Col-
lagen coated dishes were washed three times in PBS and
conditioned with serum/fetuin mix (1 mg/ml fetuin in
Ham's F12 sterile filtered (0.45 μM filter (Nalgene)) and
supplemented with 20% FBS (Cambrex), 100 μg/ml gen-
tamycin, 200 U/ml penicillin, 200 μg/ml streptomycin,
0.5 mg/ml fungizone 20 ng/ml EGF, 10 μg/ml insulin and
2 μg/ml hydrocortisone) for a minimum of 1 hour at
37°C, prior to plating cells.
Mammary epithelial cells were isolated from pregnancy
day 14.5-18.5 ICR mice. The mice were euthanised by
CO2 overdose. With care taken to avoid muscle and ten-
dons, all ten glands were removed and the tissue placed
Ham's F12 medium. The mammary glands were finely
chopped with scalpels on a Teflon board. Chopped tissue
was digested for 1.5 hours at 37°C with agitation in 70 ml
of sterile filtered collagenase mix (14 mM NaHCO3, 10
mM HEPES, 9.8 mg/ml nutrient mixture Ham's F12, 1.5Owens et al. BMC Developmental Biology 2010, 10:71
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mg/ml porcine trypsin (Gibco), 3 mg/ml collagenase B
(Roche) 5% FBS). The digested tissue was centrifuged (16
× g, 1 min) to remove any large lumps of undigested tis-
sue.
Mammary epithelial cells were then isolated as whole
alveoli, excluding fibroblasts and single cells. The super-
natant from the 16 × g, 1 min centrifugation was re-cen-
trifuged (110 × g, 3 min). The resulting pellet was re-
suspended in ice cold Ham's F12 and then washed three
times by re-suspending in Ham's F12 and centrifugation
(110 × g, 3 min). The final cell pellet was re-suspended
and combined in Ham's F12 to a final volume of 50 ml.
The mammary epithelial cells were then plated out onto
the pre-prepared collagen I coated dishes using Ham's
F12 to make up to necessary final plate volume. After 2
da ys post -pla ting t he medium was r eplac ed wit h com-
plete primary medium (10% FBS (Cambrex), 50 μg/ml
gentamycin, 100 U/ml penicillin, 100 μg/ml streptomy-
cin, 0.25 mg/ml fungizone 10 ng/ml EGF, 5 μg/ml insulin
and 1 μg/ml hydrocortisone).
Isolation of purified MECs for IAP expression analysis
was performed using a method similar to Rudolph et al
2009 [42]. In brief, purification of P18MECs was per-
formed as above, except that prior to plating, the cells
were either lysed directly in chilled lysis buffer (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Non-
idet P-40, 0.5% sodium deoxycholate, 0.1% SDS), supple-
mented with protease and phosphatase inhibitors
(Calbiochem) for protein analysis, or lysed in TriZol
reagent (Invitrogen) for RNA extraction. The purified
MECs were isolated from combined tissue extracted from
two mice at each time point.
RNA extraction and cDNA synthesis
Total RNA was extracted using TriZol reagent (Invitro-
gen), treated with DNAase I (Ambion), and integrity was
checked by agarose gel electrophoresis. To confirm that
the RNA samples were not contaminated with DNA, PCR
reactions were performed with primers to non-tran-
scribed regions of the mouse β-actin gene. RNA samples
(2.4 μg) were reverse transcribed by RevertAid First
Strand cDNA Synthesis Kit (Fermentas) using random
hexamers.
Quantitative PCR (qPCR)
Primers were selected to contain minimal intra-and inter-
primer interactions using Vector NTI 7 software (Addi-
tional files 4 and 5). Specificity was determined by
BLAST sequence alignment searches using http://
www.ncbi.nih.gov/BLAST and http://www.ensembl.org.
Primer pairs that produced a single product under opti-
mised conditions were used for quantitative analysis.
Reactions were performed using the qPCR Core Kit for
SybrGreen I (RT-SN10-05, Eurogentec). The concentra-
tions of MgCl2 and primers were optimised for each tar-
get sequence. Relative quantification of gene expression
was performed using StepOne Plus Real Time PCR Sys-
tem and StepOne Software v2 (Applied Biosystems).
Standard curves were prepared using 1:2 - 1:1000 dilu-
tions of pregnancy day 18 (sample B) cDNA. Two stan-
dard curves were prepared, one for the endogenous
reference gene β-actin and one for the target gene. To
ensure that reactions produced a single PCR product,
melt curve analyses were performed on each reaction
(and the reaction products were visualised by agarose gel
electrophoresis). The melt curve was generated by heat-
ing the reaction from 72°C to 90°C with fluorescence read
every 1°C.
Data analysis
Pregnancy day 18 (sample B) was selected as the standard
time point to which the relative expression levels of the
other time points were compared. The relative transcript
abundance of the genes of interest was obtained by nor-
malising to the transcript abundance of β-actin, which we
had validated to be a suitable normalisation gene. The
StepOne software then calculated the relative transcript
abundance of the genes of interest in the other samples
compared with P18 (sample B).
Cell culture
Primary MECs were isolated and cultured on collagen
coated dishes as described above [43]. The XIAP protec-
tion study was done using FSK7 cells [44].
Immunoblotting
Lysis of tissues or cells was performed using RIPA buffer
(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA,
1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS),
supplemented with protease and phosphatase inhibitors
(Calbiochem). Protein samples were separated by SDS-
PAGE and then transferred to nitrocellulose membrane.
Following primary antibody incubation, detection was
performed using either HRP-conjugated secondary anti-
bodies (Pierce) or IR dye-conjugated secondary antibod-
ies in conjunction with the Odyssey detection system (Li-
cor).
Additional material
Additional file 1 XIAP down-regulation in MECs is caspase-indepen-
dent. Primary MECs were cultured in complete media (lane 1), serum 
starved (lane 2), or serum starved in the presence of 100 μM zVAD, 10 ng/ml 
EGF or 5 μg/ml insulin (lanes 3, 4 and 5, respectively). (A) Whole cell lysates 
were immunoblotted with antibodies shown. (B) XIAP protein levels rela-
tive to calnexin were calculated using Li-cor Odyssey system.Owens et al. BMC Developmental Biology 2010, 10:71
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